Development

Articles

The collaboration between Bristol Myers Squibb and Century Therapeutics will combine Century’s iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.

Bristol Myers Squibb and Century Therapeutics to Collaborate on Developing iPSC-derived Allogeneic Cell Therapies

FDA has cleared an IND from Poseida Therapeutics, allowing continued development of the company’s allogeneic CAR-T cell therapy candidate for treating multiple solid tumors.

FDA Accepts IND for Poseida Therapeutics’ Allogeneic CAR-T Cell Therapy Candidate

Feliza Mirasol is the science editor for 

Sample preparation tends to be manually labor intensive, but automating this step helps streamline the glycosylation monitoring workflow.

Automation Helps Streamline Glycosylation Monitoring Workflow

There is need for training personnel in various analytical skill sets for biologic drug substance testing.

Biologics Testing Highlights Need for Analytical Skills

EMA has fully validated the marketing authorization application for Atara Biotherapeutics’ off-the-shelf allogeneic T-cell therapy, tab-cel (tabelecleucel), with an approval decision expected in 2022.

Atara Biotherapeutics' MAA for Allogeneic T-cell Immunotherapy Gets EMA Validation

Chinook Therapeutics has formed a 50/50 joint venture with investors to develop kidney disease therapies in China.

Chinook Therapeutics and Investors Form Joint Venture for Kidney Disease Therapies

BeiGene has acquired property in Hopewell, NJ to build a new manufacturing site and clinical R&D center for advanced new medicines.

BeiGene Acquires Property in New Jersey to Build Manufacturing and Clinical R&D Center

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp to Build mRNA Vaccine Manufacturing Capacity

Secarna Pharmaceuticals and Achilles Therapeutics have entered into an agreement to optimize the development of T cell therapies in Achilles’ pipeline.

Secarna Pharmaceuticals and Achilles Therapeutics Partner on T Cell Therapy Development

CGT Catapult and Deep Science Ventures have partnered to encourage innovative approaches to overcoming barriers in delivering advance therapies to patients.

Biologics APIs